Isosorbide Dinitrate And Hydralazine Hydrochloride Tablet, Film Coated
Product Images NDC 72319-012

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Isosorbide Dinitrate And Hydralazine Hydrochloride (NDC 72319-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by I3 Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier plot depicting time to death by all causes in Black patients comparing Isosorbide Dinitrate and Hydralazine Hydrochloride tablets to placebo. The graph shows percent survival over time in days, indicating a 43% reduction in mortality with treatment. Patient counts are listed at intervals along the x-axis.*

FDA Label Image

Figure2 (Figure2)

Kaplan-Meier plot comparing time to first hospitalization for heart failure in Black patients treated with isosorbide dinitrate and hydralazine hydrochloride tablets versus placebo, showing percent without hospitalization over time (days). The graph indicates a 39% risk reduction with treatment and statistical significance with a p-value less than 0.001 by log-rank test.*

FDA Label Image

Figure3 (Figure3)

A bar graph titled 'Change in Minnesota Living With Heart Failure Score' showing data over 3 to 18 months and an endpoint. It compares scores for isosorbide dinitrate and hydralazine hydrochloride tablets versus placebo. The y-axis indicates changes in the heart failure score, with lower scores representing improvement. The graph shows greater score improvements in the isosorbide dinitrate and hydralazine HCL tablets group compared to placebo at various time points. Sample sizes for each group at each time interval are shown below the x-axis.*

FDA Label Image

Figure4 (Figure4)

This figure presents results for demographic, baseline medication, and clinical characteristic subgroups in Black patients from a study labeled A-HeFT. It includes two comparative forest plots: one for all-cause mortality and another for first hospitalization for heart failure, each showing relative risk and 95% confidence intervals comparing isosorbide dinitrate and hydralazine hydrochloride tablets versus placebo.*

FDA Label Image

Hcl (Hcl)

Chemical structure of hydralazine hydrochloride, showing the molecular configuration including a hydrazine group and aromatic rings with associated hydrochloride (HCl).*

FDA Label Image

Isdn-label (Isdn Label)

Label for Isosorbide Dinitrate and Hydralazine HCl Tablets, 20 mg/37.5 mg, by i3 Pharmaceuticals, LLC. The label indicates the package contains 180 film-coated oral tablets. It includes storage instructions, manufacturer address, barcode, QR code, and revision date 05/22.*

FDA Label Image

Isdn (Isdn)

Chemical structure diagram showing the molecular structure of isosorbide dinitrate, an active ingredient in isosorbide dinitrate and hydralazine hydrochloride tablets. The diagram depicts atoms and bonds characteristic of the nitrate ester functionality.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.